Overview

Open-label Trial Evaluating Efficacy and Safety of Dasiglucagon in Children With Congenital Hyperinsulinism

Status:
Completed
Trial end date:
2020-10-05
Target enrollment:
Participant gender:
Summary
The objective of the trial is to evaluate the efficacy of dasiglucagon administered as a subcutaneous (SC) infusion in reducing hypoglycemia in children with CHI.
Phase:
Phase 3
Details
Lead Sponsor:
Zealand Pharma